The type of PD-L1 test and the way it was used by Bristol-Myers Squibb Co. could explain the failure of Opdivo in the CheckMate 026 first-line lung cancer trial, according to an editorial accompanying the study publication in the New England Journal of Medicine,and the author advises the assay used by competitor Merck & Co. Inc. is the best choice for newly diagnosed patients.
Full results for the CheckMate 026 study were published by David Carbone, Ohio State University Comprehensive Cancer Center, and colleagues...